Metrics as of 10/14/2026, 11:47 PM (Berlin time), refresh in progress.
Oramed Pharmaceuticals Stock
Oramed Pharmaceuticals Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Nadav Kidron
- Employees
- 13
- Market cap
- $169 M
- IPO
- 01/05/2007
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading…
Oramed Pharmaceuticals stock: price history
1D
-2.6%
1W
-6.0%
1M
-11.9%
6M
+4.9%
YTD
+42.8%
1Y
+79.3%
2Y
+67.5%
5Y
-81.6%
10Y
-41.5%
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~9% weaker price swings than usual
Ask the agents about Oramed Pharmaceuticals
Analyst assessment of Oramed Pharmaceuticals
0
STRONG BUY
6
BUY
2
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 17/05/2023
Oramed Pharmaceuticals stock metrics
P/E
0.98
P/B
0.54
EV/EBITDA
1.04
RETURN ON EQUITY
24.6%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
6.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
74.9%
FLOAT SHARES
31,162,027
AVG. DAILY VOLUME (30D)
171,841
Insider transactions (SEC)
Hexter Joshua
Gabay Avraham
Kidron Miriam
Kidron Miriam
Hexter Joshua
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Oramed Pharmaceuticals stock
What does Oramed Pharmaceuticals do?
Oramed Pharmaceuticals Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Nadav Kidron, the company employs around 13 people.
The IPO was on 01/05/2007; the stock trades on NASDAQ under the ticker ORMP.
What do analysts say about Oramed Pharmaceuticals stock?
8 analysts rate the stock, the consensus is Buy (as of 17/05/2023).
This is an external assessment, not a statement by Market Jury.
When does Oramed Pharmaceuticals report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -9% stronger than usual.
Does Oramed Pharmaceuticals pay a dividend?
Yes. The last dividend was US$0.25 per share, ex-date 16/01/2026, paid on 26/01/2026.
The dividend yield is 6.0% (as of 30/06/2026).
Which stocks are comparable to Oramed Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Oramed Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Oramed Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.